Year in Review 2018 by LACOG Genitourinary Cancer Group: Urological Tumors
Several and important changes in the treatment of urological tumors occurred in 2018. The studies with apalutamide (SPARTAN) and enzalutamide (PROSPER) prior to the development of metastases benefited patients with castration resistant prostate cancer. Prostate radiotherapy to the metastatic prostat...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2018-10-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.5935/1806-6054.20190003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Several and important changes in the treatment of urological tumors occurred in 2018. The studies with apalutamide (SPARTAN) and enzalutamide (PROSPER) prior to the development of metastases benefited patients with castration resistant prostate cancer. Prostate radiotherapy to the metastatic prostate cancer improves overall survival (OS) in men with new diagnosed and with low metastatic disease burden per CHARTEED criteria. In another analysis of this trial, the abiraterone improve OS even in low-risk de novo M1 castration-sensitive prostate cancer. A phase III trial (CARMENA) assessed the utility of cytoreductive nephrectomy in conjunction with TKI's and concluded that we could not offer it in intermediate and poor-risk patients of renal cell carcinoma (RCC). Combined immunotherapy with nivolumab plus ipilimumab (CHECKMATE-214) resulted in a greater objective response rate and prolonged OS in intermediate- and poor-risk patients with metastatic RCC. And in upper tract urothelial cancer, a study showed that adjuvant chemotherapy given after nephroureterectomy improves OS (POUT). |
|---|---|
| ISSN: | 2526-8732 |